{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-256290","form_type":"8-K","ticker":"SVRA","cik":"0001160308","company_name":"Savara Inc","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.908027+00:00","generated_at":"2026-05-17T01:34:59.838744+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action","bullets":["RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.","Royalty rates tiered from 7.0% to 1.0% of U.S. net sales; 7.0% tier rises to 9.5% if prior-year sales fall short.","Royalty capped at $187.5M; company expects effective rate in low-single digits over life of agreement.","Securities class action filed Sept 8, 2025 alleging misstatements about MOLBREEVI regulatory filings; company intends to defend."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-256290","json":"https://secwatch.observer/filing/0001193125-25-256290.json","markdown":"https://secwatch.observer/filing/0001193125-25-256290.md","text":"https://secwatch.observer/filing/0001193125-25-256290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/0001193125-25-256290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1160308/000119312525256290/d55049d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:34:59.838744+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}